Formulary Search Results for: CALCIUM AND VITAMIN D
6.4.1.1.1.1 Sequential combined therapy (cyclical) - View Category
6.4.1.1.1.2 Continuous combined therapy - View Category
6.6.2 Bisphosphonates and other drugs affecting bone metabolism - View Category
Restrictions:
See Prescribing notes for Formulary indications and restrictions on use.
Prescribing Notes:
Formulary Indications:
- Osteoporosis: Use in the treatment of osteoporosis in postmenopausal women is restricted to use in those patients for whom oral bisphosphonates are unsuitable, contraindicated or not tolerated in accordance with local protocol. A shared care agreement is in place for this indication and can be accessed here.
- Skeletal-related events: The prevention of skeletal related events in adults with bone metastases from solid tumours is restricted to specialist use in accordance with regional protocol where zoledronic acid is not appropriate (for example, due to renal impairment or venous access problems). Use for this indication remains specialist use only.
Non-Formulary indications:
The following indications are not recommended by SMC and remain non-formulary:
- Bone loss in prostate cancer: use in the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
- Osteoporosis in men at increased risk of fractures.
- Giant cell tumour of bone: in adults and skeletally mature adolescents when the condition is unresectable or where surgical resection is likely to result in severe morbidity.
- Prevention of skeletal related events in adults with haematological malignancies involving bone.
- Bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.
SMC advice pertaining to denosumab can be accessed here.
NICE Multiple Technology Appraisals pertaining to denosumab can be accessed here.
Near Patient Testing (NPT) arrangements for GPs may be in place for this medicine. See the relevant section in the Prescribing Resources page for current information.
5.3.1.2 Protease inhibitors - View Category
5.3.1.3 Non-nucleoside reverse transcriptase inhibitors - View Category
5.3.1.5 Other HIV combination preparations - View Category
Restrictions:
Restricted to use by HIV specialists for treatment of adults infected with HIV-1 who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor.
5.3.1.5 Other HIV combination preparations - View Category
5.3.1.5 Other HIV combination preparations - View Category
2.1.1 Cardiac glycosides - View Category
2.1.1 Cardiac glycosides - View Category
Prescribing Notes:
The management of persistent atrial fibrillation is the subject of a NHSGGC guideline